KR102966358B1 - 약학적으로 유효한 피라졸로-트리아진 및/또는 피라졸로-피리미딘 유도체 - Google Patents

약학적으로 유효한 피라졸로-트리아진 및/또는 피라졸로-피리미딘 유도체

Info

Publication number
KR102966358B1
KR102966358B1 KR1020207032377A KR20207032377A KR102966358B1 KR 102966358 B1 KR102966358 B1 KR 102966358B1 KR 1020207032377 A KR1020207032377 A KR 1020207032377A KR 20207032377 A KR20207032377 A KR 20207032377A KR 102966358 B1 KR102966358 B1 KR 102966358B1
Authority
KR
South Korea
Prior art keywords
compound
group
cancer
independently selected
case
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207032377A
Other languages
English (en)
Korean (ko)
Other versions
KR20200143429A (ko
Inventor
남기연
김재승
전의진
유동훈
서무영
박동식
얀 아익호프
군터 지스키
우베 코흐
Original Assignee
주식회사 큐리언트
리드 디스커버리 센터 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 큐리언트, 리드 디스커버리 센터 게엠베하 filed Critical 주식회사 큐리언트
Publication of KR20200143429A publication Critical patent/KR20200143429A/ko
Application granted granted Critical
Publication of KR102966358B1 publication Critical patent/KR102966358B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207032377A 2018-04-11 2019-04-11 약학적으로 유효한 피라졸로-트리아진 및/또는 피라졸로-피리미딘 유도체 Active KR102966358B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656041P 2018-04-11 2018-04-11
US62/656,041 2018-04-11
PCT/EP2019/059289 WO2019197546A1 (en) 2018-04-11 2019-04-11 Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives

Publications (2)

Publication Number Publication Date
KR20200143429A KR20200143429A (ko) 2020-12-23
KR102966358B1 true KR102966358B1 (ko) 2026-05-15

Family

ID=66334384

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207032377A Active KR102966358B1 (ko) 2018-04-11 2019-04-11 약학적으로 유효한 피라졸로-트리아진 및/또는 피라졸로-피리미딘 유도체

Country Status (14)

Country Link
US (1) US11858937B2 (enExample)
EP (1) EP3774809A1 (enExample)
JP (2) JP7406501B2 (enExample)
KR (1) KR102966358B1 (enExample)
CN (1) CN112334471A (enExample)
AU (1) AU2019250504B2 (enExample)
BR (1) BR112020020645A2 (enExample)
CA (1) CA3095426A1 (enExample)
IL (2) IL299105B2 (enExample)
MX (1) MX2020010563A (enExample)
MY (1) MY207194A (enExample)
PH (1) PH12020551638A1 (enExample)
SG (1) SG11202009466UA (enExample)
WO (1) WO2019197546A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
EP4255909A1 (en) * 2020-12-02 2023-10-11 Qurient Co. Ltd. Compounds having cyclin-dependent kinase(cdk)-inhibitory function
WO2022248682A1 (en) * 2021-05-28 2022-12-01 Qurient Co., Ltd. Compounds for degradation of cyclin-dependent kinase 7 (cdk7)
US20250042903A1 (en) * 2021-06-17 2025-02-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Triazine inhibitors of cyclin-dependent kinases
WO2023175173A1 (en) * 2022-03-18 2023-09-21 Qurient Co., Ltd. Cdk7 inhibitors for antiviral treatment
US20260041693A1 (en) 2022-08-05 2026-02-12 Qurient Co., Ltd. Combination therapy of cdk7 inhibitors with other anti-cancer therapies
KR20240095030A (ko) 2022-12-15 2024-06-25 부산대학교 산학협력단 간과 신장의 염증 및 섬유화 치료 효과가 있는 신규 트리아진 유도체 및 이의 제조방법
CN120752238A (zh) * 2023-02-20 2025-10-03 江苏正大丰海制药有限公司 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
CN120712267A (zh) * 2023-02-21 2025-09-26 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2025040170A1 (zh) * 2023-08-24 2025-02-27 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2025162425A1 (zh) * 2024-02-01 2025-08-07 广州费米子科技有限责任公司 吡唑并嘧啶化合物作为tyk2抑制剂
CN119606955A (zh) * 2024-11-13 2025-03-14 南方医科大学 Txd-174在制备治疗和/或预防黄病毒属病毒感染产品中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151304A1 (en) * 2007-06-05 2008-12-11 Emory University Selective inhibitors for cyclin-dependent kinases
WO2013128029A1 (en) * 2012-03-01 2013-09-06 Lead Discovery Center Gmbh Pharmaceutically active pyrazolo-triazine derivatives
WO2015154022A1 (en) * 2014-04-05 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP2017506250A (ja) * 2014-02-21 2017-03-02 キャンサー・リサーチ・テクノロジー・リミテッド Ｃｄｋ阻害剤としてのピラゾロ［１，５‐ａ］ピリミジン‐５，７‐ジアミン化合物及びその治療用途
JP2018507877A (ja) * 2015-03-09 2018-03-22 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ ＣＤＫ阻害剤としてのピラゾロ［１，５−ａ］［１，３，５］トリアジンとピラゾロ［１，５−ａ］ピリミジン誘導体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US615968A (en) 1898-12-13 Apparatus for treating ores
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
WO2019035866A1 (en) 2017-08-15 2019-02-21 The Brigham & Women's Hospital, Inc. COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008151304A1 (en) * 2007-06-05 2008-12-11 Emory University Selective inhibitors for cyclin-dependent kinases
WO2013128029A1 (en) * 2012-03-01 2013-09-06 Lead Discovery Center Gmbh Pharmaceutically active pyrazolo-triazine derivatives
JP2017506250A (ja) * 2014-02-21 2017-03-02 キャンサー・リサーチ・テクノロジー・リミテッド Ｃｄｋ阻害剤としてのピラゾロ［１，５‐ａ］ピリミジン‐５，７‐ジアミン化合物及びその治療用途
WO2015154022A1 (en) * 2014-04-05 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP2018507877A (ja) * 2015-03-09 2018-03-22 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ ＣＤＫ阻害剤としてのピラゾロ［１，５−ａ］［１，３，５］トリアジンとピラゾロ［１，５−ａ］ピリミジン誘導体

Also Published As

Publication number Publication date
BR112020020645A2 (pt) 2021-01-12
SG11202009466UA (en) 2020-10-29
CN112334471A (zh) 2021-02-05
CA3095426A1 (en) 2019-10-17
AU2019250504B2 (en) 2023-05-18
JP2023138859A (ja) 2023-10-02
IL299105B2 (en) 2024-02-01
JP2021521129A (ja) 2021-08-26
WO2019197546A1 (en) 2019-10-17
KR20200143429A (ko) 2020-12-23
MX2020010563A (es) 2020-10-22
US20210139483A1 (en) 2021-05-13
IL299105B1 (en) 2023-10-01
US11858937B2 (en) 2024-01-02
PH12020551638A1 (en) 2021-07-26
IL277694A (en) 2020-11-30
JP7406501B2 (ja) 2023-12-27
EP3774809A1 (en) 2021-02-17
MY207194A (en) 2025-02-05
AU2019250504A1 (en) 2020-10-15
NZ768400A (en) 2024-07-05
IL299105A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
KR20200143429A (ko) 약학적으로 유효한 피라졸로-트리아진 및/또는 피라졸로-피리미딘 유도체
KR102966455B1 (ko) 사이클린 의존성 키나아제의 선택적 억제제로서의 피라졸로-트리아진 및/또는 피라졸로피리미딘 유도체
CN112142735B (zh) 一类稠和氰基吡啶类化合物、制备方法和用途
CN102482219B (zh) 吡喃酮和吡啶酮衍生物的制备方法
CN108368089B (zh) 一种去泛素化酶抑制剂
ES2336464T3 (es) Fenilaminopirimidinas sustituidas.
BR112014021189B1 (pt) Composto, seu uso para a preparação de uma composição farmacêutica, e, composição farmacêutica contendo o mesmo
CN109069873B (zh) 作为吲哚胺2,3-双加氧酶和/或色氨酸-2,3-双加氧酶的抑制剂的新型的取代的咪唑并吡啶化合物
ES2349476T3 (es) Nuevos derivados de 4-ciano, 4-amino y 4-aminometilo de compuestos de pirazolo[1,5-a]piridinas, pirazolo[1,5-c]pirimidinas y 2h-indazol y derivados de 5-ciano, 5-amino y 5-aminometilo de compuestos de imidazo[1,2-a]piridinas e imidazo[1,5-a]pirazinas, como inhibidores de cinasa dependiente de ciclina.
US12606561B2 (en) Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors
AU2012229859B2 (en) Nitrogen-containing saturated heterocyclic compound
CN110964012A (zh) 一类稠杂环联芳基苄醇类化合物、制备方法和用途
WO2018161876A1 (zh) 二氢喹喔啉类溴结构域识别蛋白抑制剂及制备方法和用途
US20120172402A1 (en) Induction of alpha helix conformations in proteins and peptides
WO2018041260A1 (zh) 一类溴结构域识别蛋白抑制剂及其制备方法和用途
US20240343732A1 (en) Compounds for degradation of cyclin-dependent kinase 7(cdk7)
RU2818563C2 (ru) Фармацевтически активные производные пиразолотриазина и/или пиразолопиримидина
KR20260035802A (ko) 새로운 mettl3 억제제 및 치료에서의 이의 용도
EP4255909A1 (en) Compounds having cyclin-dependent kinase(cdk)-inhibitory function
JP2023526548A (ja) 新規三環芳香族複素環化合物、ならびにその調製方法、医薬組成物および適用
RU2809779C2 (ru) Производные пиразолотриазина и/или пиразолопиримидина в качестве селективного ингибитора циклинзависимой киназы
CN116693515A (zh) 一种gst蛋白抑制剂、其制备方法、药用组合物及其用途
HK1233639A1 (en) Isoquinolinone derivatives useful in the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

P14 Amendment of ip right document requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P14-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16 Ip right document amended

Free format text: ST27 STATUS EVENT CODE: A-5-5-P10-P16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16 A copy of ip right certificate issued

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q16-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000